FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.

Purpose: This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome.

Design: Fifty patients with metastatic NSCLC were included before pembrolizumab or nivolumab initiation. FDG-PET scan was performed at baseline and after 7 weeks of treatment (PET1) and different criteria/parameters of tumor response were assessed, including PET response criteria in solid tumors (PERCIST).

"Real-world" evaluation of F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy.

Objectives: The role of F-fluorocholine positron emission tomography/computed tomography (F-Choline PET/CT) in different clinical situations remains controversial and current practices are very heterogeneous. The aim of this study was to evaluate the "real-world" practice of F-Choline PET/CT in patients with prostate cancer and its potential impacts on therapeutic strategy.

Methods And Materials: This is a retrospective multicenter observational study including 265 consecutive men who underwent F-Choline PET/CT for prostate cancer between November 2014 and November 2015.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of F-FLT PET.

An emerging noninvasive approach to assess tissue proliferation uses the PET tracer 3'-deoxy-3'-F-fluorothymidine (F-FLT). To evaluate the diagnostic value of this technique in myelofibrosis, F-FLT PET imaging results were compared with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this clinical situation. Fifteen patients with histology-proven myelofibrosis were included consecutively in the study.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

PET/CT-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analyzed the clinicopathologic correlations and prognostic meaning of different patterns of bone marrow (BM) F-FDG uptake in HL.

18F-FDOPA PET for the diagnosis of parkinsonian syndromes.

18F-FDOPA PET has been historically used for the evaluation of parkinsonian syndromes in research settings. With the wider availability of PET cameras and 18F-DOPA this method can be used as a clinical diagnostic tool. Current acquisition protocols are simple with a 10 minute static acquisition performed 90 minutes post injection.